Samsung Bioepis’ Ko Insists On Value Of Data
Real-World Evidence Is Essential In Bolstering Biosimilars
In the third and final part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko talks about the importance of real-world data in bolstering biosimilars, as well as outlining the firm’s future pipeline.
